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Context: Primary bilateral macronodular adrenal hyperplasia (BMAH) is a rare form of adrenal
Cushing syndrome conventionally treatedwith adrenalectomy.Medical treatment is often reserved
for patients not eligible for surgery. However, to date there have been few studies about the
efficacy of mifepristone for the treatment of BMAH associated with hypercortisolism.
Objective: To describe a series of patients with hypercortisolism due to BMAH treated with mi-
fepristone from multiple medical practices.
Design: We retrospectively assessed four patients treated with mifepristone for hypercortisolism
due to BMAH who had either failed unilateral adrenalectomy, declined surgery, or were poor
surgical candidates.
Results: Mifepristone induced clinical improvement and remission of the signs and symptoms of hyper-
cortisolism in all described patients with BMAH. The median treatment duration at the time of efficacy
response assessment was 5 months (range: 3 to 18 months). Improvement in cardiometabolic parameters
was observed as early as 2 weeks after treatment was started. All patients achieved improvements in
glycemic control and hypertension and had significant weight loss. The most common adverse event
observed with mifepristone therapy was fatigue. Increases in TSH level occurred in two patients.
Conclusion: Mifepristone can be an effective medical alternative to surgery in patients with
hypercortisolism due to BMAH. (J Clin Endocrinol Metab 104: 6279–6290, 2019)
Primary bilateral macronodular adrenal hyperplasia(BMAH) is a rare cause of adrenal Cushing syndrome
characterized by nonpigmented nodules .1 cm in di-
ameter (macronodules) (1, 2). The degree of hyper-
cortisolism in BMAH is often mild and insidious,
although rarely, serious forms can be identified (3).
BMAH is reported predominantly in women; however,
the true prevalence of BMAH in the general population is
unknown (4, 5). The pathogenesis of BMAH involves
aberrant or amplified hormone receptor expression and
intra-adrenal secretion of corticotropin (2, 4, 6, 7). Ac-
tors of the cAMP/protein kinase A signaling pathway or
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Abbreviations: ARMC5, armadillo repeat containing 5; BLA, bilateral adrenalectomy;
BMAH, bilateral macronodular adrenal hyperplasia; BMI, body mass index; Dex-CRH,
dexamethasone-CRH; DHEA-S, dehydroepiandrosterone sulfate; DST, dexamethasone
suppression test; HPA, hypothalamic-pituitary-adrenal; LNSC, late-night salivary cortisol;
PA, primary aldosteronism; T2DM, type 2 diabetes mellitus; UFC, urine free cortisol; ULN,
upper limit of normal.
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genes causing a hereditary familial tumor syndrome,
including adenomatous polyposis coli gene (APC), menin
(MEN1), and fumarate hydratase (FH), favor the de-
velopment of BMAH (5). Additionally, in recent years
the identification of a mutation of the tumor suppres-
sor gene, armadillo repeat containing 5 (ARMC5), via
combined pan-genomic approaches has also been im-
plicated as a frequent cause of apparently sporadic or
familial BMAH (3). Somatic second-hit mutations of
ARMC5 have been found in individual adrenal nodules
of patients carrying germline ARMC5 mutations (8).
When feasible, genetic screening should be considered
because it offers a good opportunity for early diagnosis
by familial screening, treatment planning, and adminis-
tration of early therapy.
Up to 15% of adrenal adenomas are bilateral (9,
10), with less severe cortisol hypersecretion being
more common in patients with bilateral adrenal ade-
nomas compared with their unilateral counterparts
(41.5% vs 12.2%) (11). Patients with BMAH may not
present with overt signs and symptoms of Cushing
syndrome (e.g., facial plethora, proximal muscle
weakness, moon facies). However, even so-called mild
hypercortisolism is associated with several comor-
bidities, such as type 2 diabetes mellitus (T2DM),
hypertension, osteoporosis, dyslipidemia, and obesity
(12–14), as well as increased cardiovascular risk and
mortality (15–17).
Bilateral adrenalectomy (BLA) has conventionally
been considered the treatment of choice for BMAH, but it
leads to permanent adrenal insufficiency, necessitating
lifelong glucocorticoid and mineralocorticoid replace-
ment and reduced quality of life compared with the
general population (18, 19). Unilateral adrenalectomy
has recently been proposed as an alternative in select
patients, with some advocating for the removal of the
larger gland, especially in older patients (20). However,
recurrent or persistent hypercortisolism after partial
adrenalectomy has been previously reported (20–24) and
may be attributed to the initial functionality or sub-
sequent enlargement of the contralateral adrenal gland
that continues to secrete cortisol. In these cases, another
surgery to remove the remaining adrenal gland or lifelong
medical therapy may be necessary. Studies examining
recurrence of BMAH after partial adrenalectomy found
divergent rates of recurrence: one study of 15 patients
found a 13% recurrence rate in patients with at least 5
years of follow-up (21), and another of 12 patients
demonstrated a 67% recurrence rate after 4.5 years of
follow-up (24).
Mifepristone (Korlym®, Corcept Therapeutics, Menlo
Park, CA) is a competitive glucocorticoid receptor an-
tagonist medical therapy that is approved by the US
Food and Drug Administration to treat hyperglycemia in
patients with Cushing syndrome regardless of etiology.
Because of the rarity of BMAH, published data on mife-
pristone and other medical therapies related to BMAH are
limited (Table 1) (24–34). Herein, we describe a series of
patients with hypercortisolism due to BMAH who were
effectively treated with mifepristone.
Methods
A series of four patients with hypercortisolism secondary to
BMAH is described in detail to highlight the diagnostic
challenges and to illustrate a safe and effective medical
treatment strategy. These cases reflect the clinical observa-
tions reported from four individual clinical practices across
the United States. Institutional review board approval was
not required, and informed consent was obtained from each
patient.
Results
Case series results are summarized in Tables 2 and 3 and
are individually described here.
Case 1: mifepristone after failed surgery
A 71-year-old woman presented with hematuria and
underwent an abdominal CT scan (Fig. 1), which
revealed a 1.7-cm left adrenal nodule and an enlarged
right adrenal gland. Her past medical history included
nephrolithiasis at age 41, T2DM at age 58, treatment
with metformin (HbA1c 7.9%, normal ,5.7%), a long
history of easy skin bruising that worsened at age 66, and
osteoporosis with a T-score of 22.6 at the left femoral
neck. Physical examination was notable only for bruising
on her lower extremities.
Initial biochemical workup (Table 2) revealed 24-hour
urine free cortisol (UFC) findings with levels ranging
from 32 mg/d (88 nmol/d) to 116 mg/d (320 nmol/d)
[upper limit of normal (ULN) ,50 mg/d (,138 nmol/d)],
elevated mean late-night salivary cortisol (LNSC),
unsuppressed serum morning cortisol on overnight 1-mg
dexamethasone suppression test (DST) with a normal
dexamethasone level of 321 ng/dL (8179 pmol/L) [refer-
ence range 180 to 550 ng/dL (4586 to 14014 pmol/L)], and
normal serum morning ACTH.
The patient opted for a second opinion at a tertiary
center, where serial hypothalamic-pituitary-adrenal
(HPA) testing revealed 24-hour UFC levels of 62.6 mg/d
(173 nmol/d) and 50.9mg/d (140 nmol/d) [ULN,45mg/d
(,124 nmol/d)], LNSC levels of 0.83 ng/mL (2.29
nmol/L) and 1.9 ng/mL (5.24 nmol/L) [ULN ,1.0 ng/mL
(2.76 nmol/L)], and a late-night serum cortisol of 70 ng/
mL (193 nmol/L [ULN ,75 ng/mL (,207 nmol/L)]. A
dexamethasone-CRH (Dex-CRH) test found a cortisol
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level of 1.8 mg/dL (50 nmol/L) [ULN ,1.8 mg/dL
(,50 nmol/L)] at 0 minutes, followed by a cortisol level
of 2 mg/dL (55 nmol/L) [ULN,1.4 mg/dL (,39 nmol/L)]
at 15 minutes. Serial morning ACTH levels ranged
from ,5 to 14.6 pg/mL (,1.1 to 3.2 pmol/L) [normal
range 6 to 50 pg/mL (1.3 to 11 pmol/L)], and serial
evening ACTH levels ranged from 6.9 to 9.9 pg/mL (1.5
to 2.2 pmol/L) [normal ,20 pg/mL (,4.4 pmol/L)]. Be-
cause the nodule was small and biochemical tests were
equivocal, the treating physician did not recommend
surgery. Instead, mifepristone was initiated at 300 mg
once daily. After 1 week of treatment, the patient reported
fatigue, dizziness, and leg swelling. She developed mild
hypokalemia, with a potassium level of 3.4 mEq/L (nor-
mal range 3.5 to 5.0 mEq/L).
Although advised of these expected adverse events, she
elected to stopmifepristone and undergo left laparoscopic
adrenalectomy. She subsequently experienced fatigue and
dizziness postoperatively and was promptly placed on
hydrocortisone replacement therapy. Pathology revealed
BMAH with a predominant nodule.
One month postoperatively, hydrocortisone was held
for 36 hours, and assessment of serum cortisol showed
elevatedmorning serum cortisol of 25mg/dL (690 nmol/L)
[normal range 4 to 22 mg/dL (110 to 607 nmol/L)].
Because of this result, hydrocortisone was discontinued.
Table 1. Recent Reports on the Use of Medical Therapy in BMAH
Reference
Number of
Patients Treatment Duration Outcome
Obata et al. 2011 (25) 1 Trilostane 7 y Reduction of serum cortisol to upper limit of
normal
Improvement in moon facies and weight
Massive enlargement of adrenal glands
Comte-Perret et al. 2014 (26) 1 Ketoconazole 10 y Reduction of UFC to ULN
Minimal increase in adrenal glands
Recovery of ACTH
Persistent suppressed DHEA-S
Hannah-Shmouni et al. 2018 (27) 1 Leuprolide acetate 10 y Control of macromastia and mastodynia
Karapanou et al. 2013 (28) 1 Leuprolide acetate 3.3 y Biochemical control
Recovery of ACTH
Albiger et al. 2015 (24) 2 Propranolol Not reported Reduction in 24-h UFC
Persistent suppressed ACTH
Worsening of glycemic control and weight gain
Oki et al. 2009 (29) 1 Propranolol 2 y Reduction in cortisol secretion
No improvement in glucose metabolism
Mazzuco et al. 2009 (30) 1 Propranolol 8 mo Reduction in cortisol secretion
Improvement in Cushingoid features
Albiger et al. 2015 (24) 1 Octreotide LAR 5 mo Reduction in UFC
Modest clinical improvement
Patient eventually underwent surgery
Karapanou et al. 2013 (28) 1 Octreotide LAR 3 mo No control
Preumont et al. 2011 (31) 1 Octreotide 6 mo No control
Pasireotide 3 mo No control
Castinetti et al. 2009 (32) 1 Mifepristone 6 mo Improvement in hypertension and Cushingoid
features
Discontinuation of metformin after 1 mo;
decrease in HbA1c from 7.1% to 6.4%
after 6 mo
Moraitis and Auchus 2015 (33) 1 Mifepristone 3 mo Improvement in weight, Cushingoid features,
insomnia, muscle weakness, and libido
Recovery of ACTH and DHEA-S
Bourdeau et al. 2016 (34) 9 b-Blockers:
propranolol,
nadolol, atenolol,
pindolol
Up to 15 ya Reduction in cortisol response to posture test
reported in 7 patients
Partial reduction in UFC in patient with overt
hypercortisolism. Patient underwent unilateral
adrenalectomy followed by continued
b-blocker therapy, which normalized UFC.
Reduction in UFC but no reduction in cortisol
response to posture test. UFC increased over
time, and patient developed signs of Cushing
syndrome. Patient underwent BLA.
aTreatment duration not always given.
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At postoperativemonth 3, her 24-hour UFCwas 71.2mg/d
(197 nmol/d) [normal ,50 mg/d (138 nmol/d)], and
LNSC was 1.56 and 0.32 ng/mL (4.3 and 0.9 nmol/L)
[ULN ,1.56 ng/mL (,4.3 nmol/L)]. At follow-up, ab-
dominal CT revealed postoperative changes in the left
adrenal bed with surgical clips. The right adrenal was
unchanged. At 6 months, her 24-hour UFC was 78.4 mg/d
(216 nmol/d), and LNSC was 3.26 and 2.54 ng/mL (9.0
and 7.0 nmol/L), suggesting persistence of hypercortisolism.
During this time, there was no improvement in her primary
symptoms. Excessive bruising continued, and her HbA1c
worsened to 8.1%.
At this point, mifepristone was restarted. Because of
her previous objection to daily dosing, a dosage of
300 mg once a week was initiated, which was gradually
increased to 300 mg three times a week. Three months
later, her HbA1c decreased to 7.4%. She initially re-
ported fatigue, which resolved without intervention. She
Table 2. Summary of Characteristics and Laboratory Findings at Presentation
Case 1 Case 2 Case 3 Case 4
Age at diagnosis, y 71 54 71 27
Sex F F M F
BMI, kg/m2 (normal ,30 kg/m2) 19.5 43 33.2 34.3
Fasting plasma glucose, mg/dL
(normal 65–99 mg/dL)
253 139 116 115
HbA1c, % (,5.7%) 7.9 8.5 6.1 6.3
Blood pressure, mm Hg (normal
120/80 mm Hg)
129/70 141/88 170/90 156/104
Symptoms Bruising Cushingoid features Headaches Cushingoid features
Hematuria Extreme weakness Anxiety Headaches
Insomnia Anxiety
Weight gain Insomnia
Depression
Poor memory and
concentration
Dizziness
Precipitous weight gain
Cortisol after 1-mg DST, mg/dL
(normal ,1.8 mg/dL)
18 18.8 2.6 —
LNSC, ng/mLa 5.075 0.6 0.62
2.43 3.9 1.23 4.06
(ULN ,1.56 ng/mL) 2.0
(ULN ,1.5 ng/mL)
(ULN ,1.56
ng/mL)
4.28
4.93
5.4
5.58
5.62
10.26
(ULN ,1.49 ng/mL)
UFC, mg/d (normal 4–50 mg/d) 116 18.2 34.5 444.2
32 21.3 292.3
69 231.7
74
57
77
ACTH, pg/mL (normal 6–50 pg/mL) 13 Undetectable Undetectable Undetectable
Undetectableb
8.1b
14.6b
DHEA-S, mg/dL 82 (reference range
7–177 mg/dL)
36 (reference range
8–188 mg/dL)
— —
Size of nodules, cm 1.7 (left), enlargement
(right)
Diffuse enlargements 1.9–3.5 1.5–2.9
To convert cortisol and LNSC to nmol/L, multiply by 27.6.
To convert UFC to nmol/d, multiply by 2.76.
To convert ACTH to pmol/L, multiply by 0.22.
To convert DHEA-S to mmol/L, multiply by 0.0271.
aLNSC values are from different laboratories with different assays and reference ranges.
bValues from tertiary center.
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also developed mild increases in serum TSH levels,
whereas serum free T4 and free T3 levels were normal,
and antithyroid antibodies were negative. She started
levothyroxine, and her neurocognitive impairment and
depression resolved. Her HbA1c further decreased to
6.7% after 4 months of mifepristone therapy despite
complete liberalization of her diet (Table 3). Her HbA1c
was maintained until 8 months after restarting therapy,
when it increased to 7.3%. Concurrently, she also ex-
perienced recurrence of cognitive impairment despite
taking thyroid hormone and normalized TSH. Positron
emission tomography CT of the brain disclosed moderate
cortical atrophy, marked decreased activity in the pari-
etal cortex bilaterally, and moderately decreased activity
in the temporal cortex bilaterally, consistent with a
neurodegenerative process, probably Alzheimer’s dis-
ease. Fourteen months after restarting mifepristone, the
patient was admitted to the hospital for altered mental
status. At the time of hospital admission, the patient
was hypertensive (blood pressure 165/85 mm Hg) and
hyperglycemic [glucose 177 mg/dL (9.8 mmol/L)],
making adrenal insufficiency unlikely. Regardless, mif-
epristone was immediately stopped, and the patient
subsequently died of a cardiovascular event prompted
by a subcentimeter subacute right frontal lobe infarct
found on MRI.
Case 2: mifepristone in a patient who
declined surgery
A 54-year-old woman presented with Cushingoid
features and extreme muscle weakness necessitating the
use of a cane to ambulate. Her medical history included
uncontrolled T2DM (HbA1c 8.5% on short-acting sliding
scale insulin and insulin glargine 20 U at bedtime), re-
sistant hypertension (blood pressure 141/88 mm Hg)
despite administration of six antihypertensive agents,
obesity [body mass index (BMI) 43 kg/m2], dyslipidemia,
congestive heart failure, chronic obstructive pulmonary
disease, sleep apnea, chronic renal insufficiency, and
hyperthyroidism. Her blood pressure medications
Table 3. Assessments Before and After Mifepristone Treatment
Case 1 Case 2 Case 3 Case 4
Duration of mifepristone
treatment at data collection
4 mo 18 mo 3 mo 2 wk 6 mo
Maximum dosage 300 mg
3 times/wk
600 mg once daily 300 mg once daily 600 mg once daily 900 mg once daily
Before After Before After Before After Before After
ACTH, pg/mL
(normal 6–50 pg/mL)
,5 108 ,5 54 ,5 29 ,1.1 ,1.1 ,5
Fasting plasma glucose, mg/dL
(normal 65–99 mg/dL)
253 121 139 113 116 99 115 91 85
HbA1c, % (normal ,5.7%) 8.1 6.7 8.5 5.7 6.1 5.8 6.3 — —
Blood pressure, mm Hg
(normal 120/80 mm Hg)
129/70 127/81 141/88 137/81 170/90 140/80 Patient
has PA
treated with
spironolactone
156/104 122/94 98/62
Weight loss, kg 0 23.2 2.3 10.9 10
Side effects/intervention Fatigue/none Gastrointestinal
discomfort/
reduction in
mifepristone
dosage
Heat intolerance/none Fatigue, nausea, headache/
none
TSH increase/
levothyroxine
TSH increase/levothyroxine
Fatigue/none
Hypokalemia/
spironolactone
dosage increase
Clinical outcomes Reduction in
HbA1c despite
complete
liberalization of
diet
Resolution of
diabetes with
discontinuation
of insulin
Reduction in blood
pressure and HbA1c
Resolution of blood pressure
and glucose parameters
Decreased blood
pressure with
less medication
Improved anxiety, energy,
sleep
Palliation of Cushingoid
features
Improved sleep, energy,
cognitive function, and
mood
To convert ACTH to pmol/L, multiply by 0.22.
To convert fasting plasma glucose to mmol/L, multiply by 0.0555.
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included amlodipine 10 mg once daily, carvedilol 25 mg
twice daily, furosemide 40 mg once daily, hydralazine
50 mg three times daily, lisinopril 5 mg once daily, and
clonidine 0.2 mg once daily.
The patient’s Cushingoid features and clinical pre-
sentation (uncontrolled T2DM and resistant hyperten-
sion) prompted screening for hypercortisolism. Biochemical
testing indicated ACTH-independent hypercortisolism:
multiple ACTH measurements ,5 pg/mL (,1.1 pmol/L),
unsuppressed cortisol after 1-mg DST, mean 24-hour
UFC 19.8 mg/d (54.6 nmol/d) [normal ,50 mg/d
(,138 nmol/d)], mean LNSC 2.1 ng/mL (5.79 nmol/L)
[normal range 1.0 to 1.5 ng/mL (2.76 to 4.14 nmol/L)],
and low dehydroepiandrosterone sulfate (DHEA-S)
(Table 2). Additional biochemical screening ruled out
primary aldosteronism (PA) and pheochromocytoma.
Abdominal CT scans revealed diffuse bilateral enlarge-
ment of the adrenal glands, indicating BMAH (Fig. 2).
The patient declined BLA, and mifepristone was
subsequently initiated at 300 mg once daily. After
2 weeks, her fasting plasma glucose was 128 mg/dL
(7.11 mmol/L), her blood pressure decreased to 118/
80 mm Hg, and the patient lost 1.4 kg. Mifepristone
dosage was titrated to 600 mg once daily, and after
6 months of treatment her HbA1c was 5.8%, and
she lost 5 kg. After 12 months of mifepristone treat-
ment, her HbA1c had decreased to 5.6%, and she
discontinued all insulin therapy. Her weight had
decreased a total of 12.7 kg, and her blood pressure had
decreased to 130/84 mm Hg. After 18 months of mi-
fepristone treatment, HbA1c without insulin was stable
at 5.7%, her weight had decreased by 23.2 kg, she no
longer needed a cane for ambulation, and her blood
pressure was controlled (137/81 mm Hg) with fewer
medications (amlodipine 5 mg once daily, lisinopril
5 mg once daily, clonidine 0.2 mg once daily) (Table 3).
Over the course of mifepristone treatment, she developed
Figure 2. CT images from case 2 showing diffuse bilateral enlargements (arrows).
Figure 1. CT images from case 1 showing an enlarged right gland
and nodular hyperplasia on the left gland (arrows).
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hypokalemia, and spironolactonewas initiated and titrated
up to 100 mg twice daily, based on potassium and plasma
renin activity. The patient continues to use mifepristone
daily.
Case 3: mifepristone in a patient with primary
aldosteronism and cortisol cosecretion who
declined surgery
A 71-year-old man with resistant hypertension was
referred for suspected PA. He presented with daily
debilitating headaches and was found to have severe
hypertension (blood pressure of 230/100 mm Hg).
Despite initiation of five antihypertensive agents, his
blood pressure remained elevated (170/90 mm Hg).
Previously performed plasma metanephrines were
normal, as were the patient’s 24-hour UFC [34.5 mg/d
(95.2 nmol/d); normal ,50 mg/d (,138 nmol/d)] and
renal artery Doppler examination. His physical ex-
amination was notable only for central obesity. He
weighed 108.4 kg, and his BMI was 33.2 kg/m2.
Further laboratory testing revealed an aldosterone/
renin ratio of 53 ng/dL:ng/mL/h, with serum potas-
sium of 3.8 mEq/L (normal range 3.5 to 5.0 mEq/L),
suggesting PA.
An oral salt load test confirmed PA with a 24-hour
urine aldosterone of 17.9 mg/d (49.6 nmol/d). An ab-
dominal CT scan revealed four bilateral adrenal ade-
nomas ranging from 1.9 to 3.5 cm in diameter (Fig. 3).
The patient declined adrenal vein sampling and surgery.
Biochemical testing for cortisol revealed random ACTH
level ,5 pg/mL (,1.1 pmol/L), unsuppressed cortisol
after 1-mg DST, and normal LNSC (Table 2). BMAH
was diagnosed based on imaging and biochemical
evaluation.
Spironolactone was initiated for PA at 25 mg/d
and titrated to 100 mg/d over 3 months, with sub-
sequent reduction in concomitant medications.
He remained on valsartan/hydrochlorothiazide
320/25 mg once daily, with a resulting blood pres-
sure of 140/80 mm Hg.
Figure 3. CT images from case 3 demonstrating bilateral adrenal nodules. (a–c) Multiple axial views of adrenal nodules, indicated by arrows. (d)
Coronal images of bilateral adrenal nodules (arrows).
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The patient developed mastodynia associated with
spironolactone use. A trial of eplerenone (50 mg) was
initiated, but the patient’s hypertension worsened, and
spironolactone was resumed.
Over the next year, the patient developed worsening
anxiety, insomnia necessitating pharmacologic treat-
ment, weight gain of 4.5 kg, and prediabetes with HbA1c
6.1% and fasting plasma glucose 116mg/dL (6.4mmol/L)
[normal range 65 to 99 mg/dL (3.6 to 5.5 mmol/L)].
Repeat HPA axis tests showed further elevated corti-
sol after 1-mg DST of 3.4 mg/dL (93.8 nmol/L)
[ULN ,1.8 mg/dL (,50 nmol/L)] and normal LNSC of
0.83 nmol/L (ULN ,4.3 nmol/L).
Subsequently, the physician and patient decided to
start mifepristone at a dosage of 300 mg/d. After
3 months of mifepristone treatment, HbA1c and fasting
plasma glucose decreased to 5.8% and 99 mg/dL
(5.5 mmol/L), respectively. He lost 2.3 kg and re-
ported improvements in sleep, energy, and anxiety.
ACTH rose to 29 pg/mL (6.4 pmol/L), suggesting re-
covery of the HPA axis.
Case 4: presurgical use of mifepristone
A 27-year-old woman who desired pregnancy pre-
sented for evaluation of possible hypercortisolism. She
was previously healthy until ;3 years before pre-
sentation, when she began experiencing headaches,
menstrual irregularities, and unexplained weight gain.
At presentation, she was found to have new-onset
hypertension (blood pressure of 156/104 mm Hg),
prediabetes [HbA1c 6.3% and fasting plasma glucose
115 mg/dL (6.4 mmol/L)], precipitous weight gain of
30 kg in 2 years (BMI at presentation 34.28 kg/m2), and
secondary amenorrhea.
The patient complained of insomnia, depression,
anxiety, weakness, nausea, dizziness, and poor memory
and concentration. She displayed overt Cushingoid fea-
tures with dorsocervical and supraclavicular fat pads,
abdominal striae, excessive body and facial hair, skin
bruises, acne, and facial plethora.
Biochemical testing indicated severe hypercortisolism:
mean 24-hour UFC 322.7 mg/d (891 nmol/d) [ULN
,50 mg/d (,138 nmol/d)], mean LNSC 5.73 ng/mL
(15.8 nmol/L) [ULN ,1.49 ng/mL (,4.1 nmol/L)],
and mean morning ACTH ,1.1 pg/mL (0.24 pmol/L)
[normal range 7.2 to 63.3 pg/mL (1.6 to 13.9 pmol/L)].
Primary aldosteronism and pheochromocytoma were
ruled out. Abdominal CT revealed symmetrically en-
larged adrenal glands with nodules measuring 1.5 to
2.9 cm (Fig. 4).
Severe hypercortisolism placed her at risk for throm-
boembolic events and opportunistic infections, making
her ineligible for immediate BLA. Medical therapy was
administered to improve her underlying condition in
preparation for BLA. Because a rapid response was de-
sired, mifepristone was initiated at 300 mg/d. After
2 weeks, her blood pressure decreased to 122/94 mmHg,
her fasting plasma glucose decreased to 91 mg/dL
(5.1 mmol/L), and her BMI decreased to 32.43 kg/m2.
Mifepristone was titrated to 900 mg/d over
6 months, with resolution of all comorbidities. Her
hypertension resolved, fasting plasma glucose levels
decreased, and BMI further decreased to 25.26 kg/m2
(Table 3). While on mifepristone, she experienced an
increase of serum TSH levels, which resolved with
levothyroxine, and cortisol withdrawal symptoms,
which were transient and resolved without interven-
tion. Improvement in signs and symptoms of hyper-
cortisolism were noted, including weight loss of 20.9 kg,
lightening of striae, reduction of supraclavicular and
dorsocervical fat, decreased frequency of headaches,
and improved sleep, energy, cognitive function, and
mood.
A BLA was performed without complication 1 week
after the patient discontinued mifepristone. She was
treated with low-dose hydrocortisone replacement
therapy and fludrocortisone (which she continues at
maintenance dosages). The patient reported no symp-
toms of post-BLA adrenal insufficiency. Within 1 month
of adrenalectomy, her menstrual periods returned
spontaneously. Nine months after BLA, she still had not
experienced symptoms of adrenal insufficiency, her
ACTH levels were detectable, and she was able to
conceive.
Discussion
This case series suggests that medical therapy with mi-
fepristone to treat hypercortisolism associated with
BMAH is an effective and safe alternative or adjunctive
treatment modality to bilateral or unilateral adrenalec-
tomy. BLA leads to permanent adrenal insufficiency and
the need for lifelong glucocorticoid and mineralocorti-
coid replacement. Patients with adrenal insufficiency are
at high risk for potentially fatal adrenal crises (35). A
pooled analysis of 162 patients found persistent adrenal
tissue in 23% of patients who have had a BLA (36).
Treatment with unilateral adrenalectomy can result
in recurrence of hypercortisolism with rates as high as
67% because of enlargement of the contralateral
gland (20–24). For some patients, surgery may be
high risk (especially for some older adults), whereas
other patients may decline surgery for any number
of reasons, regardless of associated risk. Moreover,
irrespective of the type of surgery, comorbidities
stemming from hypercortisolism persist, leading to a
6286 Cohan et al Mifepristone Treatment in Patients With BMAH J Clin Endocrinol Metab, December 2019, 104(12):6279–6290
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article/104/12/6279/5491614 by St. Joseph’s M
edical C
enter user on 23 O
ctober 2020
poorer quality of life compared with the healthy
population (37–39).
The literature regarding medical therapy for BMAH
is limited (Table 1). Studies of trilostane, ketocona-
zole, leuprolide acetate, propranolol, and octreotide
LAR reveal a mixed picture, often resulting in no
improvement or even worsening of clinical outcomes
such as glycemic control and weight gain. Two pre-
vious reports (n5 2 patients total) on mifepristone for
the treatment of BMAH each demonstrated im-
provement in Cushingoid features, hypertension, or
weight (32, 33). In our case series, each of the four
patients, despite their varying circumstances, had
clinical improvement of hypercortisolism with
mifepristone.
Persistent hypercortisolism after failed unilateral ad-
renalectomy prompted the use of mifepristone in one
patient (case 1). In this case, additional surgery to remove
the contralateral gland was not a desired outcome, es-
pecially because the patient was elderly. Mifepristone
was able to provide an alternative to BLA and resulted in
clinical improvements that surpassed the results of pre-
vious unilateral adrenalectomies.
The patient preference to avoid adrenal surgery is
another important consideration for medical therapy, as
seen in cases 2 and 3. In such patients, some have pre-
viously advocated for active surveillance and manage-
ment of comorbid conditions without addressing the
underlying hypercortisolism. More recent studies show
that these patients can develop new comorbidities or that
their cardiometabolic profiles could worsen (39, 40). The
development of postoperative adrenal insufficiency in
248 patients who underwent adrenalectomy for mild
autonomous cortisol secretion (41) is additional evidence
of the clinical relevance of hypercortisolism. In cases 2
and 3, managing comorbidities with antidiabetes medi-
cations and antihypertensives did not improve their
cardiometabolic profiles. Their worsening metabolic
comorbidities necessitated intervention with mifepris-
tone, which resulted in immediate clinical benefit over
that generated with their previous medications. In case 2,
clinical benefits were seen in as little as 2 weeks, with
improvements in hyperglycemia, hypertension, and body
weight.
Because of its antiprogesterone activity, mifepristone
cannot be used as lifelong treatment in a young woman
Figure 4. CT images from case 4 showing sagittal and coronal views of bilateral macronodular hyperplasia (arrows).
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desiring pregnancy, as in case 4. However, her hyper-
cortisolism was so clinically and biochemically severe
that a BLA could not be immediately performed. Because
hypercortisolism causes a hypercoagulable state that
is reflected by a .10-fold increased risk of venous
thromboembolism (42), she was considered at high risk
for surgery. In fact, the Endocrine Society and others
have advocated for thromboprophylaxis in these types of
patients (43, 44). Even postoperatively, the risk of
thrombosis remains high (45). In this case, mifepristone
was used to quickly ameliorate the severe hyper-
cortisolism to prepare the patient for surgery. Mifep-
ristone resulted in clinical benefit as early as the first
2 weeks of treatment, with improvements in hypergly-
cemia, hypertension, and weight. A dosage of 900 mg
once daily over 6 months resulted in resolution of hy-
perglycemia, hypertension, and obesity, with palliation in
all signs and symptoms of hypercortisolism. All these
improvements lowered the patient’s operative risk and
expedited recovery, as evidenced by the lack of post-
operative adrenal insufficiency symptoms, spontaneous
return of menses 1 month after surgery, and subsequent
conception.
The most common adverse event observed with mi-
fepristone therapy in our case series was fatigue, which
resolved without intervention in all three patients who
experienced it. Serum TSH level increases were observed
in two patients, which necessitated initiation of levo-
thyroxine. Reversible TSH increases in patients using
mifepristone have been previously described in 19% of
patients (46). The same report described hypokalemia in
44% of patients, resulting from overactivation of the
mineralocorticoid receptor by cortisol. In our case series,
hypokalemia was observed in only one patient, which
resolved with an increase in the spironolactone dosage.
There are limitations to this case series, namely that
the data are retrospective and were derived frommultiple
clinical practices. However, given the lack of available
data, this case series of four patients offers a valuable
addition to the literature on medical therapy for BMAH.
Additional larger prospective studies are needed to de-
termine whether long-term clinical improvements with
mifepristone are sustainable and durable andwhether the
patient response to stress is altered. Published studies on
short-term mifepristone treatment in normocortisolemic
patients did not reveal any cases of adrenal insufficiency
or crises (47). Another report of short-term mifepristone
treatment in a patient with secondary adrenal insuffi-
ciency also did not result in adrenal crisis (48). However,
it remains to be seen whether long-term treatment with
mifepristone leads to different outcomes during inter-
current illnesses and stressors. Because ACTH and cor-
tisol are expected to increase on mifepristone treatment,
it also remains to be seen whether prolonged treatment
has any effects on the proliferation and function of the
remaining adrenal tissues.
In summary, our case series demonstrates the effi-
cacy of mifepristone in treating patients with hyper-
cortisolism associated with BMAH. Mifepristone
elicited substantial clinical improvements and, in some
cases, improvement in cardiometabolic parameters,
with accompanying weight loss and improvement of
Cushingoid features and neuropsychiatric symptoms
after a median treatment duration of 5 months (range 3
to 18 months). It should also be noted that these im-
provements occurred concomitantly with a reduction or
discontinuation of other medications. Mifepristone
could be considered as a treatment option for patients
with hypercortisolism associated with BMAH who
decline surgery, experienced recurrence, or need to
optimize conditions before BLA.
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